REGNRegeneron PharmaceuticalsRunning, no new patients
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Melanoma
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 1,546 (final count)
- Started
- Jul 14, 2022
- Main results expected
- Mar 12, 2026
- Fully finished
- Sep 16, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS)
Measured over: Approximately 27 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05352672 · record last updated 2026-04-22 · checked 2026-11-09 15:47 UTC